LIC shareholding in Dr Reddy's crosses 5 percent mark

This translates into an investment of Rs 1,556.41 crore to buy over 33.3 lakh shares of the pharma company.

Published On 2022-06-17 09:30 GMT   |   Update On 2022-06-17 09:30 GMT

New Delhi: LIC has raised its stake in pharma major Dr Reddy's Laboratories to over 5 percent by way of open market stock purchases during September 2021 to June this year, at an estimated cost of Rs 1,556 crore.Corporation's shareholding in Dr Reddy's Laboratories has increased from 60,64,345 to 93,96,801 equity shares, or from 3.644 per cent to 5.646 per cent of the paid-up capital of the...

Login or Register to read the full article

New Delhi: LIC has raised its stake in pharma major Dr Reddy's Laboratories to over 5 percent by way of open market stock purchases during September 2021 to June this year, at an estimated cost of Rs 1,556 crore.

Corporation's shareholding in Dr Reddy's Laboratories has increased from 60,64,345 to 93,96,801 equity shares, or from 3.644 per cent to 5.646 per cent of the paid-up capital of the said company, LIC said in a regulatory filing on Thursday.

The life insurer said it bought shares through open market purchase from September 3, 2021 to June 15, 2022 at an average cost of Rs 4,670.46.

This translates into an investment of Rs 1,556.41 crore to buy over 33.3 lakh shares of the pharma company.

Dr Reddy's is engaged in manufacturing of Active Pharamceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations.

Read also: Dr Reddy's Labs unveils Sorafenib Tablets in US

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.
Tags:    
Article Source : with agency inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News